聚乙二醇干扰素α-2b联合恩替卡韦对慢性乙肝患者RORγt eGFR的影响

doi:10.3969/j.issn.1006-6233.2020.12.036

摘要
图/表
参考文献
相关文章 (6)

全文: PDF (1250 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨聚乙二醇干扰素α-2b联合恩替卡韦对慢性乙肝患者视黄酸相关的孤儿受体(RORγt)、肾小球滤过率(eGFR)的影响。方法: 选择2017年6月至2018年6月在我院接受治疗的100例慢性乙肝患者,采用抽签法分为观察组(n=52)和对照组(n=48)。对照组给予恩替卡韦治疗,观察组加用聚乙二醇干扰素α-2b治疗。比较两组患者的临床疗效、RORγt、eGFR、T细胞亚群水平、白细胞介素-17(IL-17)、白细胞介素-4(IL-4)、干扰素-α(INF-α)水平变化情况。结果: 两组总有效率分别为75.00%、54.17%,差异显著(P<0.05);治疗前,两组RORγt、eGFR水平无显著差异;治疗后,两组RORγt、eGFR水平均有所改善,且观察组优于对照组(P<0.05);治疗后,两组T细胞亚群水平均有所改善,且观察组治疗后较对照组对比改善更明显(P<0.05);治疗前,两组血清细胞因子水平无显著差异;治疗后,两组血清细胞因子水平均有所改善,且观察组INF-α水平高于对照组,IL-17、IL-4水平低于对照组(P<0.05)。结论: 聚乙二醇干扰素α-2b联合恩替卡韦治疗慢性乙肝效果显著,可能与其可有效改善RORγt、eGFR水平有关。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：聚乙二醇干扰素α-2b, 恩替卡韦, 慢性乙肝, 视黄酸相关的孤儿受体, 肾小球滤过率

Abstract：Objective: To study the curative efficacy of pegylated interferon alpha-2b combined with entecavirin in treating chronic hepatitis B and its effects onRetinal acid-related orphan receptor (ROR gamt), glomerular filtration rate (eGFR). Methods: 100 patients of chronic hepatitis B who received therapy from June 2017 - June 2018 were selected as research objects. By lottery, they were divided into observation group (n=52) and control group (n=48). The control group was treated with entecavir, while the observation group was treated with pegylated interferon alpha - 2B, Then efficacy, ROR T, eGFR, T cell subsets, interleukin-17 (IL-17), interleukin-4 (IL-4), interferon -α(INF-α) were compared. Results: The total effective rates of the two groups were 75.00% and 54.17%, respectively, with significant differences (P<0.05). There was no significant difference in ROR T and eGFR between the two groups before treatment. After treatment, the levels of ROR T and eGFR in both groups were improved, and the observation group was better than the control group (P<0.05). After treatment, T cell subsets in both groups were improved, and the improvement in the observation group was more significant than that in the control group (P<0.05). Before treatment, there was no significant difference in serum cytokine levels between the two groups. After treatment, serum cytokine levels in both groups were improved, and the levels of INF- and IL-17 and IL-4 in the observation group were higher than those in the control group (P<0.05). Conclusion: In chronic hepatitis B patients, the application of peg interferon alpha-2b combined with entecavir has a significant effect, which can effectively improve the ROR gamma t and eGFR levels of patients.

Key words： Pegylated interferon alpha-2b Entecavir Chronic hepatitis B Retinoic acid-related orphan receptors Glomerular filtration rate

基金资助:湖北省自然科学基金项目,(编号:2009CDB1017)

引用本文:

周长雄, 于文虎, 陈卫兵, 周琴, 金笛. 聚乙二醇干扰素α-2b联合恩替卡韦对慢性乙肝患者RORγt eGFR的影响[J]. 河北医学, 2020, 26(12): 2087-2090.
ZHOU Changxiong, YU Wenhu, CHEN Weibing, et al. Curative Efficacy of Pegylated Interferon Alpha-2b Combined with Entecavirin in Treating Chronic Hepatitis B and Its Effects on RORγt EGFR. HeBei Med, 2020, 26(12): 2087-2090.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2020.12.036 或 http://www.hbyxzzs.cn/CN/Y2020/V26/I12/2087

[1] 赖思敏,赖小丽,黄汐,等.核苷(酸)类似物经治序贯聚乙二醇干扰素治疗慢性乙型肝炎的荟萃分析[J].中国感染与化疗杂志,2019,19(5):489~494.
[2] Amena A. Ahmad, Abby M. Falla, Erika Duffell,等. Estimating the scale of chronic hepatitis B virus infection among migrants in EU/EEA countries[J]. Bmc Infectious Diseases, 2018, 18(1):34.
[3] 徐勇,冯继红,李荣宽,等.不同核苷(酸)类似物治疗慢性乙型肝炎患者对eGFR的影响[J].实用肝脏病杂志,2018,21(1):50~53.
[4] Patricia dos Santos Marcon, Cristiane Valle Tovo, Dimas Alexandre Kliemann,et al. Incidence of hepatocellular carcinoma in patients with chronic liver disease due to hepatitis B or C and coinfected with the human immunodeficiency virus: A retrospective cohort study[J]. World Journal of Gastroenterology, 2018, 24(5):613~622.
[5] 杨秉辉.《慢性乙型肝炎防治指南》导读[J].中国临床医生杂志,2006,34(8):2~3.
[6] 彭亚梦,袁浩,周毅峰,等.低水平乙型肝炎病毒DNA慢性乙型肝炎患者血清乙型肝炎病毒RNA水平及其影响因素研究[J].中国全科医学,2019,22(18):2217~2222.
[7] 樊橡伟,胡勃,王向阳.肝苏胶囊联合水飞蓟宾胶囊治疗非酒精性脂肪肝合并慢性乙肝临床研究[J].陕西中医,2019,40(2):160~162,166.
[8] 嵇玮嘉,颜学兵.聚乙二醇干扰素α-2a与聚乙二醇干扰素α-2b治疗慢性乙型肝炎的效果及安全性比较[J].临床肝胆病杂志,2019,35(2):78~83.
[9] 金灵肖,倪勤,赵旭宏,等.恩替卡韦经治慢性乙型肝炎患者联合聚乙二醇干扰素α-2b提高临床治愈率研究[J].中华临床感染病杂志,2018,11(4):275~281.
[10] H. Abid, H. Meyiz, O. Laalaj,et al. Viral hepatitis B during chronic inflammatory bowel diseases at fez university hospital: prevalence and risk factors[J]. Open Journal of Gastroenterology, 2018, 8(1):17~26.